The 46th San Antonio Breast Cancer Symposium (SABCS) held from December 5th to 9th local time in San Antonio, Texas, USA was one of the world's most influential and prestigious academic event annually in the field of breast cancer research. Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group Ltd., announced that the latest data of 2 clinical studies regarding 2 assets in the company’s innovative portfolio were published at the conference.
A first-in-human clinical trial on SIM0270, a brain-penetrating selective estrogen receptor degrader (SERD) molecule independently developed by Simcere Zaiming, was presented in the POSTER SPOTLIGHT session in the form of mini oral presentation. The preliminary findings have shown good tolerability and anti-tumor activity in patients with advanced or metastatic ER+/HER2- who have undergone multiple lines of treatment.
scan QR code for more details
Whereas in another SABCS poster, the data of a pos hoc analysis of COSELA (trilaciclib), an innovative reversible CDK4/6 inhibitor co-developed by G1 Therapeutics, Inc. and Simcere revealed long-term survival benefits to patients with metastatic triple-negative breast cancer in the phase II clinical trial. Prior trilaciclib plus GCb significantly prolonged survival of patients with Triple Negative Breast Cancer who recieved subsequent anticancer therapy by nearly 20 months, compared to GCb alone.
scan QR code for more details